Niagen Bioscience, Inc. (NAGE)

NCM – Real vaqt narxi. Valyuta: USD

3.09

+0.01 (0.32%)

Bozor ochiq: Aug 12, 2026, 3:26 PM EDT

3.03

-0.05 (-1.62%)

Oldingi bozordan keyin: Aug 11, 2026, 7:55 PM EDT

12.08.2026

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL. IDEAS Conferences offer independent regional venues for top-tier companies to present their investment merits to instrumental audiences of investme.

06.08.2026

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com. The launch expands access to Tru Niagen through one of the country's largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven,.

04.08.2026

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

04.08.2026

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago.

04.08.2026

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026. Second Quarter 2026 Financial and Business Highlights Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company's website grew by 23% year-over-year. Gross margin of 64.8%, reflecting continued strength in business mix. Net income of $1.0 million, with basic and diluted earnings per.

03.08.2026

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com. The launch expands access to Tru Niagen through one of the country's largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven,.

04.08.2026

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

03.08.2026

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N.

Niagen Bioscience, Inc. (NAGE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Search stocks

Niagen Bioscience, Inc. (NAGE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168